Study #2022-1080
A pilot, open-label study of Luspatercept for patients with lower risk Myelodysplastic Syndromes (MDS) including those with Clonal Cytopenia of undetermined significance
MD Anderson Study Status
Enrolling
Treatment Agent
Luspatercept
Description
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndromes
Study phase:
Phase II
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-877-327-0346
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.